This article discusses various forms of hairloss and their psychological impacts, noting the lack of definitive treatments, but reports no new clinical findings.
This review discusses the scalp microinfusion MMP® technique for hairlosstreatment and reports no new results; it emphasizes the need for more standardized studies.
Results are not reported in this commentary, but it discusses the influence of different control group choices—an active-comparator versus non-drug users—on measuring depression risk in studies of 5-alpha reductase inhibitors.
A discussion on hairlosstreatments, including PP405, suggests it may not require consistent application but could harm existing follicles. Users also mention using Minoxidil, finasteride, and RU58841, with varying application cycles and results.
PP405 is a new hairlosstreatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
PP405 is a potential hairlosstreatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
PP-405 is a new hairlosstreatment that reactivates dormant hair follicle stem cells, differing from current treatments like minoxidil and finasteride. Some users are already using PP-405 from the grey market and report improvements.
ABS-201, a prolactin receptor blocker, shows promise in reversing hairloss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
Is Verteporfin used as a topical treatment, injection, or oral medication for hairloss?Verteporfin is an intravenous drug approved only for an eye condition; it is not approved for hair loss in any form. In the few published hair reports it was injected into the scalp alongside surgical wounding — unverified case reports of one and two patients, not trial evidence.
What side effects or limitations have been reported with Setipiprant use in hairloss research?In the one published hair-loss trial (DuBois 2021, 169 men, 24 weeks), setipiprant produced no significant hair regrowth over placebo. Treatment-related side effects — mostly mild headaches, stomach upset and fatigue — were reported in about a quarter of the setipiprant group versus just over twelve percent on placebo, and no serious events were attributed to the drug. It is an unapproved, experimental compound with no long-term safety data.
What is the best treatment for hairloss, specifically regarding hair transplants?Providers say there is no single best treatment: the choice depends on the person, with minoxidil and finasteride the common medicines and FUE a common surgical option. Only a minority of the clinics surveyed call a transplant permanent, and surgery does not stop hair loss in the hair around the grafts.